Orforglipron is a nonpeptide oral GLP-1 receptor agonist. Its US brand Foundayo was approved in April 2026, so describing it as unapproved in the United States would be outdated.
The cited approval concerns specified adults with obesity or overweight and a weight-related condition. It does not automatically establish every diabetes, age-group, cardiovascular, or jurisdictional use.
Foundayo and oral semaglutide are different molecules and products. Their administration requirements and evidence should be read separately, rather than treating an oral route as a dose-equivalence rule.
The FDA label contains important warnings, contraindications, and administration requirements. This record is a status guide and does not replace those instructions or provide a personal prescribing plan.
Regulatory status checked on 3 October 2026
United States: FDA approved Foundayo on 1 April 2026 for specified adult weight-management use alongside a reduced-calorie diet and increased activity. Current label restrictions apply.
European Union: The 14–17 September 2026 CHMP agenda lists orforglipron under assessment with outstanding issues. Subsequent EU marketing authorisation has not been verified.
Official records and primary evidence
- FDA Foundayo NDA approval letter — FDA
- FDA Foundayo approved label — FDA
- September 2026 CHMP draft agenda — EMA
Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.